As per reports, Walt Disney Co’s (DIS) cruise line has announced mandatory Covid-19 vaccination proof of all passengers above 12 years of age, traveling from Florida to the Bahamas as COVID-19 Delta variant cases across the United States surge. Travelers below the age of 12 will need a negative COVID-19 test, the cruise operator informed. Disney also plans to cancel the “Disney Fantasy” sailing on Sept. 4.
Disney’s cruise line earlier did not insist on vaccinations, but the change comes after the U.S. health regulator asked people to avoid cruises irrespective of vaccination status, as infections rise. Also, the Bahamas, which is a major hub for cruises would not allow those ships to dock in the country unless all passengers 12 years of age and above provide vaccination proof.
Dow 30 Component, The Walt Disney Company (DIS), and its subsidiaries is a diversified worldwide entertainment company that operates in four business segments: Studio Entertainment, Media Networks, Parks and Resorts, and Consumer Products & Interactive Media. To learn more about this Dow 30 Component, The Walt Disney Company (DIS), and to continue to track its progress please visit the Vista Partners Walt Disney Company, Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, and receive our FREE email updates throughout the week and view our exclusive content and research.